一例转移性癌症伴RAS野生瘤患者在mFOLFOX6加帕尼单抗治疗期间进展

K. Yoshimatsu, M. Satake, Masaki Matsumura, Yoshitomo Ito, R. Imaizumi, T. Koike, H. Yokomizo, Tatsuro Yamaguchi, S. Shiozawa
{"title":"一例转移性癌症伴RAS野生瘤患者在mFOLFOX6加帕尼单抗治疗期间进展","authors":"K. Yoshimatsu, M. Satake, Masaki Matsumura, Yoshitomo Ito, R. Imaizumi, T. Koike, H. Yokomizo, Tatsuro Yamaguchi, S. Shiozawa","doi":"10.4993/acrt.27.67","DOIUrl":null,"url":null,"abstract":"We herein report a case of metastatic colon cancer RAS wild tumor progressed during the treatment with FOLFOX + panitumumab and then recognized as BRAF mutation and MSI-H. Seventy eight years-old male patient showed anastomotic recurrence of colon cancer after curative resection of Stage II ascending colon cancer six years before the appearance of the recurrence. Six months after R0 resection, surveillance CT was performed and diagnosed as recurrent tumor invaded to duodenum. For R0 resection, mFOLFOX6 plus panitumumab therapy was initiated to expect early tumor shrinkage because of RAS wild tumor. However, tumor progressed after 4 cycles. The second-line therapy was not able to started because the disease progression was extremely rapid. He died 4 months after initiation of therapy. BRAF mutation and MSI-H were recognized from his tumor by the additional analyses.","PeriodicalId":35647,"journal":{"name":"Annals of Cancer Research and Therapy","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A case of metastatic colon cancer with RAS wild tumor progressed during the treatment with mFOLFOX6 plus panitumumab\",\"authors\":\"K. Yoshimatsu, M. Satake, Masaki Matsumura, Yoshitomo Ito, R. Imaizumi, T. Koike, H. Yokomizo, Tatsuro Yamaguchi, S. Shiozawa\",\"doi\":\"10.4993/acrt.27.67\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We herein report a case of metastatic colon cancer RAS wild tumor progressed during the treatment with FOLFOX + panitumumab and then recognized as BRAF mutation and MSI-H. Seventy eight years-old male patient showed anastomotic recurrence of colon cancer after curative resection of Stage II ascending colon cancer six years before the appearance of the recurrence. Six months after R0 resection, surveillance CT was performed and diagnosed as recurrent tumor invaded to duodenum. For R0 resection, mFOLFOX6 plus panitumumab therapy was initiated to expect early tumor shrinkage because of RAS wild tumor. However, tumor progressed after 4 cycles. The second-line therapy was not able to started because the disease progression was extremely rapid. He died 4 months after initiation of therapy. BRAF mutation and MSI-H were recognized from his tumor by the additional analyses.\",\"PeriodicalId\":35647,\"journal\":{\"name\":\"Annals of Cancer Research and Therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Cancer Research and Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4993/acrt.27.67\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Cancer Research and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4993/acrt.27.67","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

我们在此报告了一例转移性结肠癌癌症RAS野生肿瘤在FOLFOX+帕尼单抗治疗期间进展,然后被识别为BRAF突变和MSI-H。78岁男性患者,在复发出现前6年,经癌症II期上行结肠癌根治性切除术后,出现结肠癌癌症吻合口复发。R0切除6个月后,进行监测CT检查,诊断为复发性肿瘤侵犯十二指肠。对于R0切除,mFOLFOX6加帕尼单抗治疗是为了预期由于RAS野生肿瘤而导致的早期肿瘤缩小。然而,肿瘤在4个周期后进展。由于疾病进展极其迅速,二线治疗未能开始。他在开始治疗4个月后去世。BRAF突变和MSI-H通过额外的分析从他的肿瘤中被识别。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A case of metastatic colon cancer with RAS wild tumor progressed during the treatment with mFOLFOX6 plus panitumumab
We herein report a case of metastatic colon cancer RAS wild tumor progressed during the treatment with FOLFOX + panitumumab and then recognized as BRAF mutation and MSI-H. Seventy eight years-old male patient showed anastomotic recurrence of colon cancer after curative resection of Stage II ascending colon cancer six years before the appearance of the recurrence. Six months after R0 resection, surveillance CT was performed and diagnosed as recurrent tumor invaded to duodenum. For R0 resection, mFOLFOX6 plus panitumumab therapy was initiated to expect early tumor shrinkage because of RAS wild tumor. However, tumor progressed after 4 cycles. The second-line therapy was not able to started because the disease progression was extremely rapid. He died 4 months after initiation of therapy. BRAF mutation and MSI-H were recognized from his tumor by the additional analyses.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Annals of Cancer Research and Therapy
Annals of Cancer Research and Therapy Medicine-Pharmacology (medical)
CiteScore
0.70
自引率
0.00%
发文量
18
期刊最新文献
Association of Various Viral Infections with the Risk of Gastrointestinal Cancers in the Iranian Population Beta Catenin Expression in Colorectal Carcinoma and its relation to survival and prognostic factors Are Breast Cancer Awareness Campaigns Missing the Mark: Pakistan's Perspective Association between perforated peptic ulcers, human leukocyteantigen-restricted human endogenous retrovirus gene-derived peptides, and carcinogenesis after acid-suppressive therapy Comparison of the impact and quality of life of breast and lung cancer survivors in the medium-term
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1